SCHEMBL5413522

SCHEMBL5413522

CNc1nc(Nc2ccccc2C(F)(F)F)ncc1[N+](=O)[O-]

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 2/20 0.54
▸ GSK3B P49841 2/20 0.52
▸ PRKCQ Q04759 1/20 0.48
▸ ULK1 O75385 2/20 0.46
▸ LRRK2 Q5S007 8/20 0.46
▸ CYP1A2 P05177 3/20 0.46
▸ PLK1 P53350 1/20 0.46
▸ AURKA O14965 1/20 0.45
▸ GSK3A P49840 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ MCL1 Q07820 1/20 0.44
▸ PTK2B Q14289 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ IGF1R P08069 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5413325 0.83 LRRK2 (0.62) PTK2GSK3BPRKCQLRRK2CYP1A2
SCHEMBL5418647 0.82 IGF1R (0.59) GSK3BPRKCQULK1LRRK2CYP1A2
SCHEMBL5408522 0.80 LRRK2 (0.65) PTK2GSK3BPRKCQLRRK2PLK1
SCHEMBL5402268 0.79 GSK3B (0.82) PTK2GSK3BPRKCQLRRK2CYP1A2
SCHEMBL5408223 0.79 GSK3B (0.57) PTK2GSK3BLRRK2CYP1A2PLK1
SCHEMBL5415291 0.78 HDAC3 (0.49) PTK2GSK3BPRKCQULK1LRRK2
SCHEMBL5408687 0.77 IDH2 (0.56) GSK3BCYP1A2AURKAGSK3AMEN1
SCHEMBL16134079 0.76 PLK1 (0.48) PTK2GSK3BLRRK2CYP1A2PLK1
SCHEMBL1521779 0.75 GSK3B (0.53) GSK3BPRKCQCYP1A2PLK1AURKA
SCHEMBL5406396 0.75 GSK3B (0.70) PTK2GSK3BLRRK2CYP1A2PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166599-B2 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-23 — — US disclosed
US-20050090486-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-04-28 — — US disclosed
US-20030134838-A1 Trisubstituted pyrimidines BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134838-A1 Trisubstituted pyrimidines APP, PSEN1, BACE1 PTK2 4485/4885GSK3B 1515/4885PRKCQ 3253/4885
US-20050090486-A1 Trisubstituted pyrimidines APP, BACE1, PSEN1 PTK2 4507/4885GSK3B 790/4885PRKCQ 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback